1. Antoine C, Ameye L, Paesmans M, Rozenberg S . 2014. Treatment of climacteric symptoms in breast cancer patients: A retrospective study from a medication databank . Maturitas 78 : 228 – 232.
  2. Avis NE, Brockwell S, Randolph Jr JF, et al. Longitudinal changes in sexual functioning as women transition through menopause: results from the study of women’s health across the nation. Menopause 2009;16(May–June (3)):442–52.
  3. Bachmann GA, Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. American Family Physician 2000;61(May (10)):3090–6.]
  4. Mehta A, Bachmann G (2008) Vulvovaginal complaints. Clin Obstet Gynecol 51(3):549–555
  5. Morali G, Polatti F, Metelitsa EN, Mascarucci P, Magnani P, Marrè GB (2006) Open, non-controlled clinical studies to assess the efficacy and safety of a medical device in form of gel topically and intravaginally used in postmenopausal women with genital atrophy. Arzneimittelforschung 56(3):230–238
  6. Notelovitz M (1997) Urogenital aging: solutions in clinical practice.Int J Gynaecol Obstet 59:S35–S39]
  7. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. New England Journal of Medicine 1993;329(September (11)):753–6.
  8. Tea MKM, Priemer V, Kubista E (2006) Aktuelles: Wirksamkeit und Sicherheit von Hyaluron-Säure-Zäpfchen (Cikatridina(R)) bei der Behandlung hormon-oder chemotherapieinduzierter vaginaler Atrophie bei Mammakarzinompatientinnen Journal für Fertilität und Reproduktion 16 (2) (Ausgabe für Österreich), pp 17–19